CEL SCI CORP
CVMNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for CVM. That does not mean none is planned.
Get an email about CVM's next catalysts
Track CEL SCI (CVM) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
Cel-Sci Corporation (NYSE American: CVM), is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products.
Website| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
LI | Phase 3 | Squamous Cell Carcinoma of the Oral Cavity | - | - |
Frequently asked questions
What is in CEL SCI CORP's drug pipeline?→
CatalystAlert tracks 1 drug candidate in CEL SCI CORP's (CVM) pipeline across Phase 3. Its lead program is LI (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is CEL SCI CORP's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for CEL SCI CORP (CVM) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CVM biotech catalysts?→
Add CVM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow CEL SCI CORP's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.